2/12, 11:47 AM (Source: TeleTrader)
more TeleTrader news

EMA begins rolling review of CureVac COVID-19 vaccine

The European Medicines Agency (EMA) announced on Friday that it started a rolling review of CureVac's COVID-19 vaccine, also known as CVnCoV. The review will last until there is enough evidence to grant a marketing authorization application.

According to the European Union agency, non-clinical data and early clinical results showed that the vaccine triggers the production of COVID-19 antibodies.

CureVac said that it is confident is mRNA technology can help fight the COVID-19 pandemic. "Working together with the EMA to initiate a rolling regulatory process is a critical step in enabling potential access to our vaccine by the many people who still need protection from this deadly disease," Vice President Area Head Infectious Diseases at CureVac Dr. Lidia Oostvogels said.

Breaking the News / VP